The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).
Parrott
A C
AC
School of Psychology, University of East London, E15 4LZ, London, UK. a.c. parrott@uel.ac.uk
Rodgers
J
J
Buchanan
T
T
Scholey
A B
AB
Heffernan
T
T
Ling
J
J
D000818:Animals; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D006213:Hallucinogens / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D013287:Illicit Drugs / Q000009:adverse effects; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000008:administration & dosage* / Q000009:adverse effects; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000378:metabolism; D011323:Primates; D011596:Psychomotor Disorders / Q000139:chemically induced* / Q000378:metabolism
D006213:Hallucinogens; D013287:Illicit Drugs; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D004298:Dopamine